ANGO vs PACB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ANGO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
PACB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and an operating margin of -134.54%. While the company maintains a strong current ratio (5.15) and modest revenue growth (13.8%), these are overshadowed by a catastrophic 5-year price decline of 94.5% and an extreme Price-to-Book ratio of 90.56. There is a stark divergence between the analyst 'Buy' consensus and the bearish insider activity, with the CEO, CFO, and COO all selling shares. The company is currently in a high-risk survival phase with no clear path to profitability.
Compare Another Pair
Related Comparisons
ANGO vs PACB: Head-to-Head Comparison
This page compares AngioDynamics, Inc. (ANGO) and Pacific Biosciences of California, Inc. (PACB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.